Aprocitentan

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Aprocitentan, sold under the brand name Tryvio, is a medication used to treat hypertension (high blood pressure). It is developed by Idorsia. It is taken by mouth. Aprocitentan is a receptor antagonist that targets both endothelin A and endothelin B receptors. Aprocitentan was approved for medical use in the United States in March 2024. It is the first endothelin receptor antagonist to be approved by the US Food and Drug Administration (FDA) to treat systemic hypertension. The FDA considers it to be a first-in-class medication.

Aprocitentan, sold under the brand name Tryvio, is a medication used to treat hypertension (high blood pressure). It is developed by Idorsia. It is taken by mouth. Aprocitentan is a receptor antagonist that targets both endothelin A and endothelin B receptors. Aprocitentan was approved for medical use in the United States in March 2024. It is the first endothelin receptor antagonist to be approved by the US Food and Drug Administration (FDA) to treat systemic hypertension. The FDA considers it to be a first-in-class medication.

References

Text derived from https://en.wikipedia.org/w/index.php?oldid=1378609367 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

10 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.